Attention AACR-NCI-EORTC Molecular Targets Conference Registrants - Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

New Drugs on the Horizon 1

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 4 of 4
PT2385: First-in-class HIF-2α antagonist for the treatment of renal cell carcinoma
Eli M. Wallace
Peloton Therapeutics, Inc., Dallas, TX, United States
from AACR Annual Meeting 2015 on April 19, 2015 1:00 PM-3:00 PM
Unleashing anti-tumor immunity through anti-OX40 monotherapy and in combination with anti-PD-L1
Jeong M Kim
Genentech, Inc., South San Francisco, CA, United States
from AACR Annual Meeting 2015 on April 19, 2015 1:00 PM-3:00 PM
Discovery and pre-clinical pharmacology of AZD9496: An oral, selective estrogen receptor down-regulator (SERD)
Hazel Weir
AstraZeneca, Macclesfield, United Kingdom
from AACR Annual Meeting 2015 on April 19, 2015 1:00 PM-3:00 PM
Identification of LGH447: A potent and selective proviral insertion of moloney murine leukemia (PIM) 1,2 and 3 kinase Inhibitor in clinical trials for hematological malignancies
Matthew Burger
Novartis Institutes for Biomedical Research, Emeryville, CA, United States
from AACR Annual Meeting 2015 on April 19, 2015 1:00 PM-3:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 4 of 4